Infusystems Holdings, Inc. · AMEX:INFU
Infusystems — Q4 2025 Earnings Presentation
20 slides from Infusystems's earnings presentation, Feb 24, 2026
Slide 1: Helping People Live Longer and Healthier Lives
Helping People Live Longer and Healthier Lives Investor Presentation February 27, 2026 l (NYSE American: INFU)
Slide 2: Forward-Looking Statements / Non-GAAP Measures
Forward-Looking Statements / Non-GAAP Measures Forward-Looking Statements Non-GAAP Measures Certain statements contained in this presentation are forward-looking statements within the This presentation contains information prepared in conformity with GAAP as meaning of Section 27A of the Securities
Slide 3: Investment Highlights
Investment Highlights 40-Year History | Long-Term Blue Chip Customer Base 7 6 Seven Consecutive Years of Record Revenue Net Revenues $160.0 $134.9 $143.4 • Revenue CAGR: 8% $140.0 $120.0 $109.9 $125.8 • Adjusted EBITDA CAGR: 8% In Millions $102.4 $100.0 $80.0 2025 Adjusted EBITDA: $31.5M $60.0 Busin
Slide 4: Business Highlights
Business Highlights A leading provider of National scale, medical equipment and serving 19 out of patient services powered 20 top-ranked by a 100k+ device fleet Over four decades of experience, built on hospital systems in the U.S. and Canada existing Oncology therapy model and now nationwide* rapid
Slide 5: Providing Solutions To Manage the Device Throughout the Treatment Cycle
Providing Solutions To Manage the Device Throughout the Treatment Cycle Device-Agnostic Services Platform That Improves Health Care Processes and Outcomes Patient Provider • SAFE quality equipment • Equipment on demand Manufacturer • Home treatment Provider • Device agnostic • Product • distribution
Slide 6: Patient Services and Device Solutions
Patient Services Device Solutions • Oncology • Pain Management • Biomedical Services • Consumables • Wound Care • Inventory Management • Sales, Rentals & Leasing $86.5M (60%) $56.9M (40%) Total 2025 Patient Services Revenue: Device Solutions Facilitating outpatient care for $143.4 Million Providing
Slide 7: Competitive Advantages
Competitive Advantages • Significant Barriers to Entry in Patient Services • Service-Based Competitive Advantages in Device Solutions Patient Services Device Solutions • 800+ national payer • White Glove Concierge contracts covering over 97% approach of U.S. population • 7 facilities serving U.S. an
Slide 8: Patient Services
Patient Services Unique High-Service Platform, Third-Party Payer Model INFU Is Paid by the Patient’s Insurance Provider Device Clinical Support/ Logistics Case Management Device Repair & “The patient is at Revenue Cycle Maintenance the center of Management everything we do.” Oncology (Core Business)
Slide 9: Device Solutions
Device Solutions Traditional Medical Distribution, Direct Payer Model INFU Is Paid Directly by the Hospital/Clinic/Home Care Provider Sales, Rentals Inventory & Leasing & Tracking Medical Device Trusted Device & Service Provider Device Repair & Consumable Maintenance Sales • Device Solutions (Core B
Slide 10: Managing the Device Throughout the Treatment Cycle
Managing the Device Throughout the Treatment Cycle Connecting and Enhancing Processes for Key Stakeholders To Solve Complex Problems Manufacturer Provider • Distribution • Devices on demand • Device support • White Glove services • Third-party payer billing SOLUTIONS Payer Patient • Improved outcome
Slide 11: High-Value Health Care Services Platform
High-Value Health Care Services Platform Specialized Skills We Developed for Oncology Now Being Leveraged in New Therapies and Partnerships 11
Slide 12: InfuSystem's Unique Capabilities Are in High Demand
InfuSystem's Unique Capabilities Are in High Demand April 2022 February 2021 Biomedical Master August 2024 Acquired and Service Agreement Announced Integrated Two With Leading Global Distribution April 2023 Agreement With February 2020 Biomedical Services Health Care Technology Announced National Sm
Slide 13: Quarterly Trends
Quarterly Trends Net Revenue Quarterly Trend Adjusted EBITDA Quarterly Trend (1)(2) $40.0 $10.0 $36.0 $36.5 $36.2 $34.7 $35.3 $8.8 $33.7 $33.8 $9.0 $8.3 $32.0 $31.7 $31.9 $31.8 $8.0 $7.9 $30.4 $8.0 $7.5 $30.0 $28.8 $26.8 $27.0 $27.3 $7.0 $26.6 $26.5 $6.5 $24.8 $6.2 $6.3 $6.2 $6.2 $24.5 $6.1 $5.9 $5.
Slide 14: Annual Financial Performance
Annual Financial Performance Net Revenues Adjusted EBITDA (1)(2) $160.0 $35.0 $143.4 $31.5 $134.9 $140.0 $125.8 $30.0 $26.2 $25.3 $120.0 $109.9 $24.0 $102.4 $25.0 $22.4 $ in Millions $ in Millions $97.4 $20.7 $100.0 $20.0 $80.0 $15.0 $60.0 $40.0 $10.0 $20.0 $5.0 $— $— 2020 2021 2022 2023 2024 2025 2
Slide 15: Annual Margin Performance
Annual Margin Performance Gross Margin Adjusted EBITDA Margin (1)(2) 59.4% 30.0% 57.2% 56.0% 26.9% 60.0% 55.1% 50.2% 52.2% 25.0% 23.5% 50.0% 21.9% 20.0% 18.9% 18.8% 17.8% 40.0% 30.0% 15.0% 20.0% 10.0% 10.0% 5.0% —% —% 2020 2021 2022 2023 2024 2025 2020 2021 2022 2023 2024 2025 Patient Services Gross
Slide 16: Balance Sheet Highlights
Balance Sheet Highlights Fixed vs. Floating Debt $ in Millions As of December 31, 2025 null Equity $57.3 Total Long-Term Debt $19.6 Net Leverage Ratio 0.52x Debt/Equity Ratio 0.75x $19.6M Total Available Liquidity $58.2 Effective Fixed Interest Rate on Fixed 3.8% Debt 100% Cash Provided by Operation
Slide 17: Capital Allocation Priorities
Capital Allocation Priorities Investments to Drive Organic Growth Initiatives • Device Solutions – Biomedical Services • Patient Services – SI Health Care Technologies Reduce Debt Levels • Ongoing Financial Flexibility • Maintain Leverage at 1.5x – 2.0x Share Repurchase – Opportunistic • $20M Stock
Slide 18: Corporate Priorities
Corporate Priorities Maintain Solid Core Business in Oncology and Device Solutions Drive Major Growth Initiatives – Biomedical and Wound Care Continuous Process Enhancements to Boost Net Margins; Sustain Optimal CapEx Efficiency Balance Investment/Growth Initiatives With Improving AEBITDA and Cash F
Slide 19: Appendix A GAAP to NON-GAAP Reconciliation
Appendix A GAAP to NON-GAAP Reconciliation Twelve Months Ended Three Months Ended NET INCOME TO ADJUSTED EBITDA: December 31, December 31, (in thousands) 2021 2022 2023 2024 2025 2024 2025 GAAP net income $ 1,420 $ 18 $ 872 $ 2,345 $ 6,627 $ 933 $ 2,036 Adjustments: Interest expense 1,377 1,402 2,17
Slide 20: Executive Team
Executive Team Seasoned Industry Experience Health Care Medical Device Life Sciences Carrie Lachance Chief Executive Officer & Director Pharmaceutical Joined InfuSystem: 2010 Military Consulting Public Accounting Information Technology & High-Tech Automotive Barry Steele Addam Chupa Jerod Funke Exec